Breaking News

Fujifilm Diosynth To Make ThromboGenics Drug

November 14, 2012

Will provide commercial supply for Jetrea launch

Fujifilm Diosynth Biotechnologies will provide commercial product supply of Jetrea (ocriplasmin) following ThromboGenics’ FDA approval for the treatment of Symptomatic Vitreomacular Adhesion (VMA).
 
The two companies entered a long-term commercial supply agreement for the manufacture of bulk substance in September 2010, following the completion of Phase III trials, and have partnered to complete validation and establish a well-characterized process.
 
Steve Bagshaw, managing director of Fujifilm Diosynth Biotechnologies’ Billingham, UK, said, “We are delighted that ThromboGenics has received FDA approval for the launch of Jetrea in the U.S. It is very gratifying for our team to see that their hard work in developing and manufacturing the product over the years has resulted in a drug being available to people suffering from distressing ophthalmic conditions. This is fifth licensed biopharmaceutical manufactured by Fujifilm Diosynth Biotechnologies and the second made at our Billingham site.”
 
Dr. Patrik De Haes, chief executive officer of ThromboGenics, said, “Fujifilm Diosynth Biotechnologies has been a key partner in helping to bring our first drug to market. The team at Billingham has done an excellent job in developing and validating a robust process and manufacturing material to enable us to launch the product on schedule.”
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks